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Acute lymphoblastic leukemia and other aggressive lymphoid malignancies like Burkitt leukemia/lymphoma have high incidence
of central nervous system (CNS) involvement. Various solid tumors, most notably breast cancer, can also metastasize into the CNS
as a late stage complication causing devastating effects. Intrathecal (IT) chemotherapy consisting of methotrexate, cytarabine, or
the two in combination is frequently used for the prophylaxis and treatment of CNSmetastasis. Because of the high toxicity of these
chemotherapeutic agents, however, their side effect profiles are potentially catastrophic. The incidence of neurotoxicity secondary
to IT chemotherapy is well defined in the pediatric literature but is poorly reported in adults. Here, we investigated the incidence
of neurologic and nonneurologic side effects secondary to IT chemotherapy in 109 consecutive adult patients over a two-year time
period at hospitals associatedwith our institution. Of 355 IT chemotherapy treatments received by these patients, 11 (3.10%) resulted
in paresthesias or paralysis, which we defined as significant neurologic events in our analysis. We also examined minor events that
arose after IT chemotherapy, including back pain, headache, fever, vomiting, and asthenia. At least one of these occurred after
30.70% of IT chemotherapy doses. Clinicians involved in the care of patients receiving IT chemotherapy should be aware of these
findings and consider treatment options lower rate of neurotoxicity such as high-dose systemic methotrexate.
1. Introduction
Advances in the treatment of many hematological and solid
tumor malignancies have improved disease-free survival
rates. Unfortunately, such improvements have come with
increased frequency of relapses in the leptomeninges or CNS
parenchyma, most commonly in aggressive lymphoid malig-
nancies such as acute lymphoblastic leukemia (ALL), Burkitt
lymphoma/leukemia, and lymphoblastic lymphoma [1–4].
Leptomeningeal metastasis can also complicate solid tumors,
breast carcinoma being the most commonly associated [5].
Several treatments have been developed to target malignant
cells in the CNS to prevent these events, most commonly
intrathecal (IT) chemotherapy. The chemotherapeutic agents
approved for intrathecal use in the United States include
methotrexate, cytarabine, liposomal cytarabine, and thiotepa
[1, 5, 6]. The scheduling and dosing of these medications
varies depending on whether they are used for prophylaxis
or treatment. Corticosteroids are frequently included with IT
chemotherapy, most commonly hydrocortisone, to increase
cytotoxicity and to decrease the risk of chemical arachnoiditis
[1].Most prophylactic regimens for leukemia and lymphomas
contain methotrexate, either as a single agent or in combina-
tion with cytarabine.
The goal of IT chemotherapy is to maximize CNS drug
exposure through direct CSF introduction, while reduc-
ing systemic drug toxicities [2]. The narrow therapeutic
index and high potential toxicities of these agents mean
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IT administration can have potentially catastrophic conse-
quences. Chemical arachnoiditis, an acute syndrome occur-
ring hours after injection and characterized by headache,
backache, vomiting, fever, meningismus, and cerebral fluid
pleocytosis, is among the most common and potentially
serious effects [1, 7]. More severe symptoms also have been
reported including cauda equina syndrome, encephalitis,
papilledema, myelopathy, paraplegia, cranial nerve palsies,
and seizures [7–11]. It is possible that the incidence of
neurological complications in this setting is underestimated
because cases may go unrecognized or unreported. To
better characterize the incidence of neurological compli-
cations secondary to IT therapy, we examined sequential
adult patients who received it over a two-year period
at our institution. We documented signs and symptoms
of neurotoxicity not present before administration that
developed acutely thereafter. We provide illustrative case
example followed by analysis of events in 109 consecutive
patients.
2. Methods
We included adult patients with hematologic and solid
tumors who received IT chemotherapy between January
2014 and December 2015 at Jackson Memorial Hospital and
Sylvester Comprehensive Cancer Center. Primary endpoint
studied was development of new symptoms indicative of
neurotoxicity and/or arachnoiditis within fourteen days of
administration of IT chemotherapy, specifically paralysis,
paresthesias, headache, back pain/nuchal rigidity, asthenia,
fever, nausea, or vomiting. Additional sensory and sphincter
disturbances, which may also be associated with arach-
noiditis, were not reliably documented and were excluded
from analysis. We defined paralysis and paraesthesias as
significant neurologic events for the purposes of analysis
and the other side effects as minor events. This division
was to allow distinction between more serious neurologic
toxicities associated with IT chemotherapy from events with
less impact on quality of life and/or of a more systemic
nature.
Known CNS involvement was defined as follows: (1) CSF
positive for malignancy by cytology and/or flow cytometry
from samples collected at the time of administration or
previously in association with the patient’s current malig-
nancy; (2) contrast enhanced MRI of the brain and/or spinal
cord showing leptomeningeal carcinomatosis according to
attending radiologist’s report [12].
Patient and disease variables were compared between
treatment modalities using the chi-square test for categorical
data and the Mann-Whitney U test for continuous data. Rel-
ative risk was estimated using univariate Poisson regression
models to assess the effect of these characteristics on a specific
adverse event with respect to the treatment modalities. Tests
were two-sided, and findings were considered statistically
significant at p<0.05. All analyses were performed using SAS
and R software.
This study was a retrospective chart review that did not
involve any interaction with patients and therefore specific
informed consent from each patient was not required by
our Institutional Review Board. Any information that might
lead to the identification of individual patients has been
excluded. All procedures followed were in accordance with
the ethical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2008.
3. Results
3.1. Illustrative Case, Severe Neurologic Complications of IT
Chemotherapy. A61-year-oldHispanic womanwith a history
of stage IV diffuse large B-cell lymphoma (DLBCL) was
admitted for salvage therapy with rituximab, dexametha-
sone, high-dose cytarabine, and cisplatin (R-DHAP). She
previously had completed six cycles of rituximab, cyclophos-
phamide, adriamycin, vincristine, and prednisone (R-CHOP)
with twelve milligrams of intrathecal (IT) methotrexate
(MTX) prophylactically in each cycle.
On day 1 of R-DHAP the patient received IT MTX 12 mg
with cytarabine 50mg. Flow cytometry and cytology from the
lumbar puncturewere negative formalignancy.The following
day the patient complained of a nonpositional headache rated
as 7 out of 10 in intensity. The headache was associated with
photophobia, nausea without vomiting, and double vision.
She denied neck stiffness or fever. Acetaminophen did not
relieve the pain but sumatriptan provided mild relief. On
day three she reported bilateral lower extremity weakness,
right greater than left. She also reported inability to ambulate
secondary to the weakness, rectal incontinence, and urinary
retention. Weakness progressed in the days that followed to
bilateral lower extremity paralysis.
Neurologic exam was significant for right lateral rectus
paresis (with the rest of the cranial nerve exam unre-
markable), decreased strength of all muscle groups in the
bilateral lower extremities, diminished reflexes in the bilateral
patellar and Achilles tendons, positive Babinski on the right,
and diminished sensation to light touch over the sacrum,
posterior thighs, and perineum. The physical exam findings
were not present prior to administration of IT chemother-
apy. Six days after symptom onset repeat LP again yielded
negative cerebrospinal fluid (CSF) studies for involvement by
malignant cells. CSF total protein was elevated to 131 mg/dL,
glucose and total cell count were within normal limits, and
gram stain and culture were negative. Lumbar and thoracic
spine MRIs revealed mild enhancement of the ventral and
dorsal nerve roots of the cauda equina, particularly at
T12-L3, and diffuse central spinal cord signal abnormality
most prominent from T6-L2 (Figure 1(a)). Brain magnetic
resonance imaging (MRI) showed symmetric FLAIR signal
abnormality in the brainstem and cerebellum without dif-
fusion restriction or abnormal enhancement (Figures 1(b)-
1(d)).
No other etiology for her symptoms was identified, and
they were attributed to intrathecal chemotherapy-induced
neurotoxicity. The patient did not recover neurologic func-
tion, and her systemic lymphoma unfortunately progressed
soon thereafter. She entered hospice care and died secondary
to complications of her systemic lymphoma.
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Figure 1:MRI images of severe IT chemotherapy complications. (a) Increased T2 signal throughout the spinal cord, most prominent from T6
to the conus. There is some associated cord expansion. The cord signal involves almost the entire diameter most noted at T8. (b-d) Brain
images showing symmetric FLAIR signal abnormality in the brainstem, cerebellum, and possibly the thalami without diffusion restriction or
abnormal enhancement.
3.2. Consecutive Case Series. During the study period, 109
patients received IT chemotherapy, of whom 74 (68%) were
male and 35 (32%) were female. Forty-four (40%) were
Hispanic. The median patient age was 50 years old; the age
range was 20 to 88 years old. The most common diagnosis
was diffuse large B-cell lymphoma (40%), followed by B-
cell ALL (28%), T-cell ALL (8%), and Burkitt lymphoma
(8%). Sixteen (15%) of patients were HIV positive and 3
(2.8%) had chronic renal failure. At time of treatment,
33 (30%) patients had CNS involvement (Table 1). The
median number of IT chemotherapy doses per patient was 2
(range 1-12).
Therapy consisted of methotrexate alone, cytarabine
alone, or methotrexate + cytarabine. Neither thiotepa nor
topotecan was used at either institution in adult patients
during the time period in question. The total number of IT
doses recorded was 355. There were 150 doses of methotrex-
ate alone, 18 of cytarabine alone, and 187 of cytarabine +
methotrexate.
Rates of each symptom per administration of IT
chemotherapy are shown in Table 2 and Figure 2. We also
determined the rate at which each symptom occurred
per patient over the all doses administered (Table 2). The
significant neurologic events paralysis and/or paresthesias
occurred after 11 doses (3.10%) affecting 9 patients (8.26%).
Minor events occurred after 109 doses (30.70%) affecting
29 patients (26.61%). We documented only new-onset
symptoms because the systemic changes fever, nausea,
vomiting, and asthenia, which may be associated with
chemical arachnoiditis, may also occur for other reasons
in this patient population (see Discussion). We compared
rates of adverse events among the three treatment modalities
but did not detect any significant differences (Table 2).
When liposomal cytarabine (Depocyte) was compared to the
nonliposomal formulation, there was again no significant
difference in rates of adverse neurologic events. There was
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Figure 2: Rates of adverse effects of IT chemotherapy. Percentage of
355 IT chemo doses associated with each side effect in a series of 109
consecutive patients.
significant correlation, however, between the number of IT
treatments a patient received and likelihood of experiencing
at least one adverse effect (correlation coefficient 0.35,
p=0.001).
We also examined correlation between adverse neuro-
logic events and independent variables, specifically HIV
status, renal failure, and known CNS involvement. Patients
with known CNS involvement were found to have risk of
any event with borderline statistical significance (RR=2.9,
95%CI=0.99-8.49, p=0.052) but with high significance when
considering only minor events (RR=4.35, 95%CI=1.85-10.24,
p=0.0008). There were no differences detected in patients
who had renal failure or HIV.
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Table 1: Patient population and disease characteristics.
Variable N %
Gender
Female 35 32.1
Male 74 67.9
Race/Ethnicity
Non-Hispanic White 20 18.3
Non-Hispanic Black 17 15.6
Hispanic White 42 38.5
Hispanic Black 2 1.8
Asian 2 1.8
Haitian 4 3.7
Other/unknown 22 20.2
Type of Cancer
DLBCL 43 39.4
B-Cell ALL 31 28.4
T-Cell ALL 8 7.3
Burkitt Lymphoma 8 7.3
Breast Cancer 3 2.8
Other Non-Hodgkin 7 6.3
CML 1 0.9
CLL 1 0.9
Other 4 3.7
Chronic Renal Failure
Yes 3 2.8
No 106 97.2
HIV
Yes 16 14.7
No 93 85.3
CNS Involvement
Yes 33 30.3
No 76 69.7
4. Discussion
Overall incidence of acute neurotoxicity from IT MTX in
children is 3-11% [13], but review of the literature reveals rates
are not well defined in adults. We report rates of significant
adverse neurologic events following IT chemotherapy used
as either prophylaxis or treatment for known leptomeningeal
involvement at ourmedical center over a two-year period.We
found these events occurred after 3.1% of IT chemotherapy
doses, affecting 8.26% of the patients in our consecutive case
series. Minor side effects were more common, occurring
after 30.70% of doses and affecting 26.61% of patients at
least once during the course of their therapy. We found
a strong correlation between number of IT treatments
received and likelihood of suffering at least one adverse effect.
Headache, nausea, vomiting, back pain, and fever were most
common—all of which are known symptoms of chemical
arachnoiditis. Our results indicate an incidence of neurologic
side effects secondary to intrathecal chemotherapy in adults
significantly higher than for children and which may be
higher than what is commonly perceived by practitioners.
Although symptoms such as headache and back pain
related to lumbar puncture are not uncommon, clinicians
should also be cognizant that these symptoms may signify
impending onset of more significant toxicity. Methotrex-
ate is typically assumed to be the major cause of such
neurotoxicities [13], but cytarabine is also a known major
cause [14–16]. Our series did not reveal any differences
in relative risk of neurologic side effects between MTX,
cytarabine, or the two in combination. Jabbour et al. eval-
uated neurologic complications secondary to IT liposomal
cytarabine in combination with high-dose methotrexate as
prophylactic treatment in patients with ALL and found the
incidence of severe complications to be 16% [8]. A smaller
retrospective review by Ga´llego Pe´rez-Larraya et al. studying
IT liposomal cytarabine given as prophylaxis in patients with
non-Hodgkin lymphoma reported 28% of patients developed
moderate or severe neurotoxicity [14]. Pretreatment with
oral dexamethasone has been found to decrease adverse side
effects of depot form of cytarabine (DTC) [17].
IT chemotherapy for both therapy and prophylaxis
of CNS involvement has been a mainstay for medical
Journal of Oncology 5
Table 2: Adverse neurologic events.
No. of patients
affected (%)
No. of Events (
occurrence rate per IT
treatment)
Treatment RR 95% CI P Value
Significant
Neuro Events 9 (8.26) 11 (3.10)
Overall∗
MTX 1 - -
CYT 1.67 0.19-14.27 0.641
MTX and
CYT 1.16 0.50-2.71 0.728
Paresthesias 8 (7.34) 10 (2.82)
MTX 1 - -
CYT 1.67 0.19-14.27 0.64
MTX and
CYT 0.64 0.17-2.39 0.51
Paralysis∗∗ 2 (1.83) 3 (0.85)
MTX 1 - -
CYT 8.33 0.52-133.23 0.134
MTX and
CYT 0.80 0.05-12.82 0.876
Minor Events 29 (26.61) 109 (30.70)
Overall∗
MTX 1 - -
CYT 1.53 0.75-3.12 0.241
MTX and
CYT 0.97 0.66-1.41 0.857
Asthenia 4 (3.67) 10 (2.82)
MTX 1 - -
CYT 2.78 0.56-13.76 0.21
MTX and
CYT 0.80 0.26-2.49 0.703
Headache 15 (13.76) 50 (14.08)
MTX 1 - -
CYT 1.23 0.43-3.53 0.694
MTX and
CYT 0.68 0.39-1.19 0.180
Back pain 9 (8.26) 18 (5.07)
MTX 1 - -
CYT 2.08 0.44-9.81 0.353
MTX and
CYT 1.00 0.40-2.54 0.996
Fever 5 (4.59) 19 (5.35)
MTX 1 - -
CYT 2.78 0.56-13.78 0.211
MTX and
CYT 1.47 0.54-3.98 0.447
Nausea 13 (11.93) 48 (13.52)
MTX 1 - -
CYT 0.93 0.21-3.99 0.918
MTX and
CYT 1.25 0.69-2.26 0.464
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Table 2: Continued.
No. of patients
affected (%)
No. of Events (
occurrence rate per IT
treatment)
Treatment RR 95% CI P Value
Vomiting 6 (5.50) 32 (9.01)
MTX 1 - -
CYT 1.11 0.25-4.86 0.889
MTX and
CYT 0.91 0.45-1.82 0.788
∗Multiple major or minor events simultaneously are counted only once in overall (overall numbers are therefore less than total of subcategories).
∗∗One patient had both paresthesias and paralysis in two events. To avoid double-counting, these events were included only in paresthesias for the RR
calculation.
management of leukemia and lymphoma throughout the
world for several decades and for patients with lep-
tomeningeal involvement by solid tumors [7]. Survival for
patients with leptomeningeal spread of disease, however,
is low while the incidence of early and late complications
associated with IT chemotherapy can be high [18–20]. Several
studies have suggested that systemic high-dose (HD) MTX
may improve the response rate or survival of patients with
CNS involvement [18, 19]. Glantz et al. treated 16 patients
with neoplastic meningitis from a variety of solid tumors
and lymphoma with HD MTX alone and retrospectively
compared outcomes to 15 patients treated with standard IT
chemotherapy [19]. Significantly longer median survival was
found in patients who received HD IV MTX (13.8 months)
compared to those who received IT MTX (2.3 months;
P=0.003). Daily CSF samples were collected and MTX con-
centrations were measured, revealing that IV administration
achieved superior CSFMTX levels. As the flow of CSF is from
the ependymal cells in the brain down to the cauda equina
where it is resorbed, the administration of IT MTX to the
area between L2 and L3 was suboptimal. IT topotecan has
been used with some success in pediatric malignancies based
on favorable pharmacokinetic properties [21, 22]. In adults,
however, IT topotecan as a single agent did not produce
clinical benefit over standard therapies in a multicenter
phase 2 trial for patients with meningeal involvement by
any malignancy [23]. A later case series, however, showed
anecdotally particular patients may achieve clinical benefit
lasting up to 12 months from IT topotecan [24].
Olmos-Jimenez et al. performed an observational and
prospective study in Spain evaluating standardized triple
intrathecal chemotherapy in adult hematology-oncology
patients over an 18-month period [25]. Similar to our
study, adverse events occurring after administration of IT
chemotherapy was recorded; however this study was substan-
tially smaller containing only 20 patients and 56 treatments.
The study population was 75% male, 50% of the patients
had non-Hodgkin lymphoma, and 5% had pre-existing lep-
tomeningeal disease. Adverse events occurred after 39.3% of
56 doses recorded. The vast majority of events (96.7%) were
grades 1-2 with only one event being grade 3. As in our study,
the adverse event recorded most frequently was headache,
followed by vomiting and vertigo. One administration event
(1.8%) resulted in grade 2 sensorimotor polyneuropathy.
5. Limitations
Because our study was retrospective, the ability to determine
causality of symptoms is limited and we acknowledge that the
population studied had additional reasons to develop some
of the symptoms reported. Given the disparate underlying
malignancies of the patients in our series, we did not investi-
gate systemic chemotherapy as a confounder; future studies
should investigate whether concurrent administration of
agents that may cause neuropathy, such as vincristine, may
lead to increased rates of neurologic events with administra-
tion of IT chemotherapy. We believe for the great majority of
incidents we analyzed here, however, the timing of the symp-
toms in relation to IT chemotherapy administration reflects a
likely causative link. An additional caveat of this study is that
we could not specifically separate out prophylactic measures
such as administration of hydrocortisone as independent
variables in our analysis due to low numbers and incom-
plete documentation of nonpharmacologic interventions.
Questions regarding efficacy of interventions designed to
prevent IT chemo toxicities are likely best answered through
prospective studies. Use of the Common Toxicity Criteria
(CTC) to define symptoms was considered and would have
made the side effects we report more easily comparable to
experiences at other institutions. This was not possible for
the purposes of this retrospective analysis, however, in which
patient charting did not consistently follow the criteria. This
is another matter for which a prospective study would be well
suited.
6. Conclusion
The most common approach for prevention of CNS spread
of hematologic tumors is IT chemotherapy, with or without
radiation. Its use should not be discarded, but practition-
ers should be aware of the potential complications and a
frequency that may be higher than commonly perceived.
Consideration of alternate, less toxic forms of therapy such
as systemic HDMTX may be warranted and, as highlighted,
could be more effective in some cases.
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